Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 13/20 | 0.78 |
| ▸ | S100A4 | P26447 | 4/20 | 0.70 |
| ▸ | P4HB | P07237 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732841 | 0.88 | SOAT1 (1.00) | SOAT1S100A4P4HBG6PDCDC25B | |
| SCHEMBL15732931 | 0.86 | SOAT1 (1.00) | SOAT1S100A4P4HBPTPN1G6PD | |
| SCHEMBL15732808 | 0.86 | SOAT1 (1.00) | SOAT1S100A4P4HBPTPN1G6PD | |
| SCHEMBL15732972 | 0.86 | SOAT1 (1.00) | SOAT1S100A4P4HBPTPN1G6PD | |
| SCHEMBL15732984 | 0.86 | SOAT1 (1.00) | SOAT1S100A4P4HBPTPN1G6PD | |
| SCHEMBL358334 | 0.86 | SOAT1 (1.00) | SOAT1S100A4P4HBPTPN1G6PD | |
| SCHEMBL2599427 | 0.83 | SOAT1 (1.00) | SOAT1S100A4P4HBAPAF1ALDH1A1 | |
| SCHEMBL17445487 | 0.79 | SOAT1 (0.51) | SOAT1S100A4P4HBPTPN1APAF1 | |
| SCHEMBL4629512 | 0.79 | S100A4 (0.76) | SOAT1S100A4PTPN1APAF1ALDH1A1 | |
| SCHEMBL7106792 | 0.76 | SOAT1 (1.00) | SOAT1S100A4P4HBCDC25BMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888326-B1 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RES FOUND (US) | 2006-08-16 | — | — | EP | claimed |
| JP-2000506841-A | — | — | 2000-06-06 | — | — | JP | claimed |
| US-5977187-A | 4-substituted-1,2-naphthoquinones and their use in the inhibition of neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | claimed |
| EP-0888326-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997031936-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-09-04 | — | — | WO | claimed |
| WO-2008066300-A1 | NAPHTHOQUINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-0888326-B1 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RES FOUND (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050010060-A1 | Novel quinones as disease therapies | SLIL BIOMEDICAL CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-5977187-A | 4-substituted-1,2-naphthoquinones and their use in the inhibition of neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5883270-A | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0888326-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0886524-A2 | DELIVERY OF THERAPEUTIC AGENTS TO THE PROSTATE | CHIRON CORPORATION (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997031611-A2 | TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031936-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010060-A1 | Novel quinones as disease therapies | NQO1, NDUFV2, SDHB | SOAT1 1552/4885S100A4 3300/4885P4HB 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.